Appeals Court Rules in Favor of Merck
A recent report confirmed that Merck & Co. (MRK) has managed to get a US appeals court ruling in its favour, which would prohibit Mylan Inc. (MYL) from selling a generic version of the Zetia and Vytorin cholesterol medicines before April 2014 when the patent expires.
It was claimed that Mylan had approached the U. S. Court of Appeals for the Federal Circuit in Washington over patenting the active ingredient in the drug, ezetimibe. "The appellate court appropriately upheld the lower court's ruling in April 2012 that found the patent for Zetia and Vytorin is valid and enforceable", said Ron Rogers, a Merck spokesman.
If reports are to be believed, Zetia generates as much as $1.33 billion while Vytorin ropes in $764 million. However, sales of Vytorin of late have been going down due to its ineffectiveness in dealing with the cases.
Moreover, the spokesperson has gone onto say that they would keep on investing time and money in research and development, in order to come out with better and better drugs and there would be no compromise made whatsoever in defending their intellectual property rights. Mylan has not responded to the decision made by the .S. appeals court on Thursday.
New Zealand News
- Porsche reportedly developing electric version of 718 sports car
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- Plug-in cars’ share grows to 32% in Netherlands in September 2021
- Italian motorcycle racer Valentino Rossi enters e-bike business with VR46 MTB range
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain